| Type | Subsidiary |
| Parent Company | Biogen |
| HQ | Newton, MA, US |
| Founded | 2008 |
| Website | karyopharm.com |
| Cybersecurity rating | BMore |
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Karyopharm Therapeutics
Sharon Shacham
President and Chief Scientific Officer, Founder
Garen Bohlin
Director
Brian Austad
Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten
Director
Tina Beamon
Vice President, Chief Compliance Officer
Yosef Landesman
Senior Vice President, Research and Translational Medicine
Karyopharm Therapeutics Office Locations
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Alon Towers 1, 94 6789155, Yigal Alon St
Karyopharm Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2008 |
Total Funding | $248.7 m |
Investors | New Leaf Venture Partners, Delphi Ventures, Foresite Capital |
Karyopharm Therapeutics is a subsidiary of Biogen
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics's revenue was reported to be $40.89 m in FY, 2019
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 171.0k | 21.0k | 21.0k | 150.0k | 75.0k | 59.0k | 48.0k | 68.0k | 19.9m | 239.0k | 155.0k | 9.5m | 13.1m | 18.1m | 33.5m | 21.3m | ||||||
Cost of goods sold | 1.0m | |||||||||||||||||||||
Gross profit | 12.1m | |||||||||||||||||||||
Gross profit Margin, % | 92% |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 52.9m | 144.9m | 132.3m | 227.1m | 51.5m | 24.2m | 43.5m | 42.2m | 37.7m | 43.9m | 25.6m | 55.4m | 54.5m | 37.5m | 119.0m | 101.6m | 83.5m | 75.5m | 168.0m | 202.2m | 103.1m | 82.3m |
Accounts Receivable | 7.9m | 9.3m | 9.6m | |||||||||||||||||||
Prepaid Expenses | 658.0k | 2.7m | 3.0m | 4.2m | 2.9m | 4.1m | 3.1m | 1.7m | 1.5m | 3.4m | 2.1m | 2.1m | 2.1m | 2.4m | 3.4m | 4.8m | 7.0m | 5.7m | 5.3m | 7.6m | 8.0m | 8.2m |
Inventories | 100.0k | 970.0k | 1.7m | 2.0m |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.8m) | (13.7m) | (30.1m) | (49.8m) | (26.1m) | (58.8m) | (89.1m) | (27.1m) | (57.2m) | (82.6m) | (29.9m) | (59.3m) | (89.9m) | (38.5m) | (72.1m) | (120.2m) | (66.2m) | (109.6m) | (150.9m) | (52.9m) | (99.4m) | (152.9m) |
Depreciation and Amortization | 106.0k | 43.0k | 85.0k | 191.0k | 136.0k | 292.0k | 457.0k | 179.0k | 358.0k | 537.0k | 183.0k | 363.0k | 539.0k | 169.0k | 353.0k | 541.0k | 245.0k | 487.0k | 730.0k | 242.0k | 480.0k | 715.0k |
Inventories | (100.0k) | (624.0k) | (1.3m) | (1.7m) | ||||||||||||||||||
Accounts Payable | 673.0k | 1.5m | 1.7m | 362.0k | 268.0k | (1.8m) | (2.1m) | 294.0k | 233.0k | (1.7m) | (522.0k) | (1.5m) | (2.9m) | (773.0k) | (1.9m) | (3.4m) | (2.0m) | (3.2m) | (1.2m) | 711.0k | 903.0k | 1.4m |
- Source: SEC Filings
| USD | Q3, 2013 |
|---|---|
Financial Leverage | -1.2 x |
Karyopharm Therapeutics Cybersecurity Score
Karyopharm Therapeutics Environment, Social & Governance (ESG) Ratings
Karyopharm Therapeutics Online and Social Media Presence
Karyopharm Therapeutics's Trends
Karyopharm Therapeutics News and Updates
December 21, 2020
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....
September 20, 2019
KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…
September 17, 2019
Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc.
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CURLF) Lifshitz & Miller announces investigation into possible securities laws violation in connection with the FDA's warning letter to Curaleaf stating that several of CURLF's CBD products were "misbranded drugs" in...
August 02, 2019
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI
NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...
July 27, 2019
KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...
July 25, 2019
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
NEW YORK, NY - (NewMediaWire) - July 25, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal s…
Karyopharm Therapeutics Blogs
January 11, 2021
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
-- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 --
December 18, 2020
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
-- Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addressable Patient Population --
December 07, 2020
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
-- In a Randomized Investigator Sponsored Study, XPOVIO in Combination with Standard Induction and Consolidation Chemotherapy Demonstrated Improved Survival in Older, Fit Patients with Acute Myeloid Leukemia -
December 07, 2020
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting
-- Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating Once Weekly XPOVIO with Low-Dose Dexamethasone Combinations Continue to Demonstrate Favorable Response Rates and Durability in Patients with Previously Treated Multiple Myeloma --
Karyopharm Therapeutics Frequently Asked Questions
When was Karyopharm Therapeutics founded?
Karyopharm Therapeutics was founded in 2008.
Who are Karyopharm Therapeutics key executives?
Karyopharm Therapeutics's key executives are Sharon Shacham, Garen Bohlin and Brian Austad.
How many employees does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 437 employees.
What is Karyopharm Therapeutics revenue?
Latest Karyopharm Therapeutics annual revenue is $40.9 m.
What is Karyopharm Therapeutics revenue per employee?
Latest Karyopharm Therapeutics revenue per employee is $93.6 k.
Who are Karyopharm Therapeutics competitors?
Competitors of Karyopharm Therapeutics include CytomX Therapeutics, Calithera Biosciences and AVEO Pharmaceuticals.
Where is Karyopharm Therapeutics headquarters?
Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.
Where are Karyopharm Therapeutics offices?
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.
How many offices does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies